In lab studies, the orally active drug has been shown to degrade the VAV1 protein expressed in T- and B- cells. VAV1 is thought to be a signalling protein involved in the production of pro ...
Investor's Business Daily on MSN4mon
Monte Rosa Almost Doubles — Up 94% — On A Massive Deal With NovartisMRT-6160 degrades a protein called VAV1. "Overall, we see this favorable collaboration agreement as additional robust ...
Company to present clinical results from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader MRT-6160 and Phase 1/2 study of MRT-2359 in MYC-driven solid tumors Conference call and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback